Onesource Specialty Pharma Limited — Board Meeting, 23-01-2026: Outcome of Board Meeting

OneSource Specialty Pharma announced its board meeting outcome. The company reported a Q3 consolidated loss after tax of ₹88.70 Cr on revenue of ₹290.34 Cr. The Board also noted the ongoing Composite Scheme of Amalgamation and a significant unresolved claim from Prestige Biopharma regarding a Sputnik vaccine contract.